Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

Completed · Phase 2

Conditions studied: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome

In brief

RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

Key facts

Study ID

NCT00027638

Run by

Memorial Sloan Kettering Cancer Center

Starts

2001-03-01

Expected to finish

2003-12-01

Last updated by the study team

2013-06-18

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.